Paper Details

  1. Home
  2. Paper Details

Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea.

Author: GarlandScott, PiszczatoskiChris, PowellJason

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Solriamfetol, a novel wakefulness-promoting agent, has been approved by the FDA for the treatment of excessive sleepiness related to narcolepsy and obstructive sleep apnea. The review summarizes clinical trial data supporting its safety and efficacy, suggesting it may be a valuable option for managing excessive sleepiness.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The purpose of this article is to review the available clinical trial data that led to the Food and Drug Administration (FDA) approval of solriamfetol as well as its role in clinical practice. DATA SOURCES: A MEDLINE/PubMed search was conducted (January 2000 to February 2020) using the k...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/1060028020915537

データ提供：米国国立医学図書館（NLM）

Solriamfetol: A Novel Approach to Excessive Sleepiness

Excessive sleepiness (ES) can significantly impact quality of life. This research reviews the clinical trial data that led to the Food and Drug Administration (FDA) approval of solriamfetol for the treatment of ES associated with narcolepsy and obstructive sleep apnea (OSA). The study examines the efficacy, safety, and unique mechanism of action of this novel medication.

A Promising New Option: Solriamfetol for Excessive Sleepiness

The study findings indicate that solriamfetol demonstrates dose-dependent improvement in wakefulness compared to placebo, offering a potential new treatment option for ES in narcolepsy and OSA. The researchers highlight solriamfetol's distinct mechanism of action, which may reduce its abuse potential compared to other stimulants.

Managing Sleep Disorders: A Multifaceted Approach

This research underscores the need for individualized treatment strategies for sleep disorders. The study findings suggest that solriamfetol may be a valuable addition to the therapeutic armamentarium for managing ES in narcolepsy and OSA. Patients with ES should discuss their concerns and treatment options with their healthcare provider.

Dr. Camel's Conclusion

Fighting excessive sleepiness can be like battling a relentless desert heat—finding the right medication can make a world of difference. This research provides a detailed look at the potential of solriamfetol as a novel treatment option for ES, offering hope for improved wakefulness and quality of life.

Date :
  1. Date Completed 2020-12-31
  2. Date Revised 2020-12-31
Further Info :

Pubmed ID

32270686

DOI: Digital Object Identifier

10.1177/1060028020915537

Related Literature

Article Analysis
・Effects of solriamfetol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.